In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars: A New Kind Of Innovation

Executive Summary

The lesson from first-generation biosimilars is that these aren't just small-molecule style copies. They require significant clinical and commercial support to overcome prescriber skepticism. For those lining up to tap into the next-generation opportunity, biosimilars represent a new kind of innovation, where the novelty lies in a drug's value-focused pricing, quality, cost-effective production, and in peripherals such as support-services and means of delivery. Although biosimilar market dynamics will vary from molecule to molecule, this emphasis on price and value rather than scientific breakthrough exemplifies a new definition of innovation in the biopharma sector.

Advertisement

Related Content

Beyond Herceptin, Roche Readies Breast Cancer Successors, Braces For Biosimilars
Post Biocon, Pfizer Pushes Forward On Biosimilar MABs
Pfizer’s Biosimilar Program: A MAB Dash After Biocon Deal Ends
Pfizer’s Biosimilar Program: A MAB Dash After Biocon Deal Ends
The US Biosimilar Pathway: Unclear Just How Abbreviated, But Could Provide Useful Biosimilar 'Stamp'?
Ipsen/Inspiration’s Coagulation Factor IX Accepted For Review By EMA
And Now For The Real Biosimilar Opportunity: Antibodies And Complex Biologics
Biosimilars: Nearly The End Already, Or Is The Best Yet To Come?
Opening A Door To Biosimilars In The US
Merck Likes Biosimilars, But Not ESAs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003711

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel